However, a small heterogeneity was found in the analysis for the risk of laryngeal cancer (I2 = 69.1%, P < 0.001), in which the type of antibodies, experimental methods of IHC, and cutoff values for evaluating COX-2 expression might lead to the heterogeneity. This evidence concerns the gene PTGS2 and laryngeal carcinoma.